Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, postponed its IPO on Wednesday. The Boston, MA-based company was founded in 2006 and had planned to list on the NASDAQ under the symbol GLSS. Piper Jaffray,...read more
Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering.
The company's lead candidate uses its proprietary hydrogel technology...read more
Vitae Pharmaceuticals, which uses software to develop small molecule drugs for type 2 diabetes and Alzheimer's, announced terms for its IPO on Monday. The Fort Washington, PA-based company plans to raise $60 million by offering 5.0 million shares at a price...read more
Vitae Pharmaceuticals, which is using advanced software to design drugs for type 2 diabetes and Alzheimer's, filed on Tuesday with the SEC to raise up to $55 million in an initial public offering. The company claims its drug delivery platform, Countour, uses...read more
Obesity biotech Gelesis does not float shares; $52 million IPO postponed
Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, postponed its IPO on Wednesday. The Boston, MA-based company was founded in 2006 and had planned to list on the NASDAQ under the symbol GLSS. Piper Jaffray,...read more
The latest weight loss capsule: Gelesis files for a $60 million IPO
Gelesis, which is developing a weight loss capsule for patients with obesity and type 2 diabetes, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering. The company's lead candidate uses its proprietary hydrogel technology...read more
Diabetes/Alzheimer's biotech Vitae Pharmaceuticals sets terms for $60 million IPO
Vitae Pharmaceuticals, which uses software to develop small molecule drugs for type 2 diabetes and Alzheimer's, announced terms for its IPO on Monday. The Fort Washington, PA-based company plans to raise $60 million by offering 5.0 million shares at a price...read more
Diabetes/Alzheimer's biotech Vitae Pharmaceuticals files for a $55 million IPO
Vitae Pharmaceuticals, which is using advanced software to design drugs for type 2 diabetes and Alzheimer's, filed on Tuesday with the SEC to raise up to $55 million in an initial public offering. The company claims its drug delivery platform, Countour, uses...read more